News

Stealth BioTherapeutics Initiates Clinical Study of Bendavia for the Treatment of Mitochondrial Myopathy

Stealth BioTherapeutics, a biopharmaceutical company developing treatments for rare, mitochondria-related diseases, recently announced the initiation of a new clinical study of Bendavia for the treatment of Mitochondrial Myopathy (MM). Mitochondrial Myopathy (MM) is rare genetic condition that affects the mitochondria, a cell’s “center” responsible for maintaining the body’s energy, causing progressive muscle…

MitoAction hosts 4th Mitochondrial Disease Clinical Conference

As part of its ongoing effort to improve mitochondrial disease patient care, MitoAction — a nonprofit organization dedicated to improving the quality of life for children, adults, and families living with mitochondrial disease through support, education, outreach, advocacy, and clinical research initiatives — in collaboration with the organization’s Medical Advisory…